Takeda Pharmaceutical Company （TAK） 2023年度综合报告「NYSE」.pdf

1、 2023 ANNUAL INTEGRATED REPORT Fiscal Year ended March 31,2023 About TA K E DA I S A G LO B A L values-based,research and development(R&D)-driven biopharmaceutical company committed to achieving our corporate purpose:better health for people and a brighter future for the world.We strive to deliver t

2、ruly transformative treatments,signifcantly increasing the value that we bring to society.2023 Annual Integrated Report 2About Governance Patient People Planet Financials Global CSR Appendix 2 About Governance Patient People Planet Financials Global CSR Appendix 3 2023 Annual Integrated Report 32023

3、 Annual Integrated Report CEO LETTER D E A R STAK E H O L D E R S,At Takeda,the patients we serveand achieving outcomes for them and their healthhave been at the heart of everything we do for more than 240 years.Today,with health care systems increasingly under strain as life expectancies rise,popul

4、ations age and innovative treatment options expand,our patient-centered and outcomes-focused approach is more relevant than ever.In our 2023 Annual Integrated Report,Im pleased to share the progress we have made over the past year to deliver on our purpose of better health for people and a brighter

5、future for the world.We are positioning ourselves for long-term sustainable growth,innovation and resilience while staying rooted in our core values of Integrity,Fairness,Honesty and Perseverance,brought to life through actions based on patient,trust,reputation and business,in that order.Innovating

6、with Patients in Mind Public health care systems built on a fee-for-service model are facing signifcant fnancial and resource strain,and the restrictive drug pricing and reimbursement policies adopted in some countries in an efort to alleviate the pressure,raise concerns about the impact on R&D inve